In vitro synergistic effects of various combinations of vancomycin and non-beta-lactams against Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors :: Kang YR
Chung DR
Kim J
Baek JY
Kim SH
Ha YE
Kang CI
Peck KR
Song JH
Source :: Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2016 Nov; Vol. 86 (3), pp. 293-299. Date of Electronic Publication: 2016 Aug 15.
Publication Year :: 2016
Abstract: The aim of our study was to determine the potential for synergistic effect of vancomycin combined with a non-beta-lactam agent and of combinations of orally available non-beta-lactam agents against vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA). Three VISA isolates, three hVISA isolates, and two vancomycin-susceptible S. aureus (VSSA) isolates were used. The combinations included vancomycin and one of clindamycin, ciprofloxacin, gentamicin, rifampicin, or trimethoprim/sulfamethoxazole. Pairwise combinations among five non-beta-lactam agents were also tested for synergy. Synergy was determined using time-kill curves at 24h. Vancomycin combined with either ciprofloxacin or gentamicin showed synergy against some isolates of VISA, hVISA and VSSA. Vancomycin combined with trimethoprim/sulfamethoxazole showed synergy against VISA and hVISA. Among orally available non-beta-lactam agents, only ciprofloxacin combined with either clindamycin or trimethoprim/sulfamethoxazole showed synergy against one isolate of VISA.<br /> (Copyright © 2016 Elsevier Inc. All rights reserved.)

Subjects :: Bacteremia microbiology
Humans
Microbial Sensitivity Tests
Microbial Viability drug effects
Staphylococcal Infections microbiology
Staphylococcus aureus isolation & purification
Staphylococcus aureus physiology
Anti-Bacterial Agents pharmacology
Drug Synergism
Staphylococcus aureus drug effects
Vancomycin pharmacology
Vancomycin Resistance drug effects

Full Text Access

Tools